Is Waiting Longer for New Prescription Drug Approvals Necessarily a Bad Thing?

 Why Canada’s ‘slow and low’ approach to new pharmaceuticals may be the prudent approach. The newest report from Canada’s brand name drug makers on access to new drugs has one key message: compared to other countries, Canada goes slow and low.  New drugs are slower to be covered by our